$268.93 Million in Sales Expected for Exelixis, Inc. (NASDAQ:EXEL) This Quarter

Equities analysts forecast that Exelixis, Inc. (NASDAQ:EXEL) will report sales of $268.93 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Exelixis’ earnings. The lowest sales estimate is $255.02 million and the highest is $304.36 million. Exelixis reported sales of $226.92 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 18.5%. The firm is expected to report its next quarterly earnings results on Tuesday, May 4th.

On average, analysts expect that Exelixis will report full-year sales of $1.23 billion for the current fiscal year, with estimates ranging from $1.15 billion to $1.35 billion. For the next financial year, analysts anticipate that the company will post sales of $1.65 billion, with estimates ranging from $1.48 billion to $1.82 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Exelixis.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 9th. The biotechnology company reported $0.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.04. The business had revenue of $270.10 million during the quarter, compared to the consensus estimate of $261.44 million. Exelixis had a net margin of 15.88% and a return on equity of 8.55%. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 EPS.

EXEL has been the subject of several research analyst reports. Morgan Stanley reduced their price target on shares of Exelixis from $29.00 to $27.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 16th. Piper Sandler increased their target price on shares of Exelixis from $33.00 to $36.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 16th. Wolfe Research assumed coverage on shares of Exelixis in a research report on Wednesday, March 17th. They issued an “outperform” rating and a $35.00 target price for the company. TheStreet upgraded shares of Exelixis from a “c” rating to a “b-” rating in a research report on Wednesday, February 10th. Finally, William Blair reiterated a “buy” rating on shares of Exelixis in a research report on Friday, January 15th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $31.67.

Shares of NASDAQ:EXEL traded up $0.46 during mid-day trading on Monday, hitting $23.88. The stock had a trading volume of 13,398 shares, compared to its average volume of 2,232,530. The company has a market cap of $7.45 billion, a PE ratio of 48.79, a P/E/G ratio of 1.27 and a beta of 1.21. Exelixis has a 12-month low of $17.54 and a 12-month high of $27.80. The company’s 50 day moving average is $22.58 and its 200-day moving average is $21.91.

In related news, CFO Christopher J. Senner sold 30,000 shares of the firm’s stock in a transaction on Tuesday, January 12th. The shares were sold at an average price of $25.00, for a total value of $750,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Gisela Schwab sold 50,000 shares of the firm’s stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $23.00, for a total transaction of $1,150,000.00. The disclosure for this sale can be found here. Insiders sold a total of 495,317 shares of company stock worth $11,214,343 over the last quarter. 4.50% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of EXEL. Perigon Wealth Management LLC acquired a new stake in Exelixis in the 4th quarter worth $39,000. Advisory Services Network LLC grew its position in Exelixis by 164.0% in the 4th quarter. Advisory Services Network LLC now owns 2,360 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 1,466 shares during the last quarter. Laffer Tengler Investments acquired a new stake in Exelixis in the 4th quarter worth $52,000. TD Ameritrade Investment Management LLC acquired a new stake in Exelixis in the 4th quarter worth $63,000. Finally, Blume Capital Management Inc. grew its position in Exelixis by 16.0% in the 4th quarter. Blume Capital Management Inc. now owns 3,712 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 512 shares during the last quarter. Institutional investors own 81.37% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: Put Option Volume

Get a free copy of the Zacks research report on Exelixis (EXEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com